STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Scott MILLER

Confirmation No.: 8682

Serial No.: 09/776,936

Examiner:

KUMAR, Shailendra

Filed:

December 22, 1998

Group Art Unit:

1621

Title:

INHIBITION OF RAF KINASE USING SYMMETRICAL AND

UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

United States Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

TIMING AND FEES

	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this informati disclosure statement is filed:				
		within three months of the filing date of a national application other than a CPA under § 1.53(d);			
		within three months of the actual filing date of the national phase of a PCT application; OR			
		before the mailing of a first substantive office action (including after filing of an RCE).			
\boxtimes		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the s specified in 37 C.F.R. § 1.97(b), but before the mailing date of:			
	\boxtimes	a final rejection under 37 C.F.R. § 1.113;			
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			
		a notice of allowance under 37 C.F.R. § 1.311; and			

02/14/2005 MBELETE1 00000062 09776936

01 FC:1806

180.00 OP

	is accompanied by:						
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR				
		\boxtimes	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).				
	Under mailin	37 C.F g date o	F.R. § 1.97(d), this information disclosure statement is filed after the of the following actions which have not been withdrawn:				
		a final	action under 37 C.F.R. § 1.113;				
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR				
		a notic	e of allowance under 37 C.F.R. § 1.311;				
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:				
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).				
STATE	MENTS	Under	37 C.F.R. 1.97(e)				
	in a co	ach item of information contained in this information disclosure statement was cited a communication from a foreign patent office in a counterpart foreign application aving a mailing date not more than three months prior to the filing date of this information disclosure statement; or					
	a comit to the item o any in	municat knowle f inforn dividua	formation contained in this information disclosure statement was cited in the form a foreign patent office in a counterpart foreign application, and edge of the undersigned attorney after making reasonable inquiry, no nation contained in this information disclosure statement was known to I designated in 37 C.F.R. § 1.56(c) more than three months prior to the the information disclosure statement.				
CITED	MATE	RIALS					
	ancest	or appli	terials listed but not attached were cited in benefit (35 U.S.C. § 120) ication Serial No, on Form 892 by the Examiner and/or Form opplicant; see 37 C.F.R. § 1.98(d).				
	Copies dated		terials listed but not attached were cited in an international search report				
\boxtimes	Copies	s of the	materials listed are attached (except for the foregoing).				
Non-l	Englisi	H LANG	UAGE REFERENCES				
			nguage search report or equivalent paper from a foreign patent office is cating the relevance of the cited reference(s).				

	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
	A = document defining the general state of the art
	O = non-written disclosure P = intercalated document
	T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and
	which was published only on or after this filing date D = cited in the application
	L = cited for another reason
	& = publication of member of same patent family
	Translation of other relevant information on foreign search report
Отне	R INFORMATION
	None
<u>Раум</u>	ENT OF FEES DUE (IF ANY):
\boxtimes	A check for \$180.00 covering the fee identified above is attached.
	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.
\boxtimes	The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account No. 13-3402, two copies of this paper are attached for this purpose.
	Respectfully submitted,
	Pile II To Page No. 30 505
	Richard J. Traverso, Reg. No. 30,595 Attorney/Agent for Applicant
	EN, WHITE, ZELANO &
	BRANIGAN, P.C. pton Courthouse Plaza 1, Suite 1400
	Clarendon Boulevard
	ton, Virginia 22201
_	none: (703) 243-6333 nile: (703) 243-6410

(RJT/slm) K:\bayer\6 p1\IDS & 1499.doc

Date: February 10, 2005

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE sarabalized to respond to a collection of information unless it contains a valid OMB control number. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person

	Substitute	for form 1449A/P1	ro		Complete if Known			
				•	Application Number	09/776,936		
	INFO	RMATION	I DIS	CLOSURE	Filing Date	DECEMBER 22, 1998		
	STAT	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	PPLICANT	First Named Inventor	SCOTT MILLER			
	• • • • • • • • • • • • • • • • • • • •				Group Art Unit	1621		
		(use as many sl	heets as	necessary)	Examiner Name	KUMAR, Shailendra		
7	Sheet	1	of	1	Attorney Docket Number	BAYER-0006-P01		
		·	•					

		U.S. Patent Do	cument	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
Examiner Initials *	Cite No.1	Number	Kind Code ² (if known)		
	i i				

		Fo	reign Patent Doc	ument		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number ⁴	Kind Code⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵
		1						
					-			

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C1	Ravi et al., "Activated Raf-1 Causes Growth Arrest in Human Small Cell Lung Cancer Cells," J. Clin. Invest., Vol. 101, No. 1, January 1998, 153-159
	C2	Nicholas R. Lemoine, "Overview of ras oncogenes and their clinical potential," pp. 85-91

Examiner Signature	Date Considered	,
		_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding